Ascentage Pharma Group International 将来の成長

Future 基準チェック /36

Ascentage Pharma Group International利益と収益がそれぞれ年間53.7%と26.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に49.8% 55.2%なると予測されています。

主要情報

53.7%

収益成長率

55.2%

EPS成長率

Biotechs 収益成長	43.4%
収益成長率	26.6%
将来の株主資本利益率	49.8%
アナリストカバレッジ	Good
最終更新日	04 Dec 2024

今後の成長に関する最新情報

Recent updates

What Ascentage Pharma Group International's (HKG:6855) P/S Is Not Telling You

Dec 23

Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up

Sep 04

Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

Aug 26

Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Jun 18

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

May 03

Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Mar 30

Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

Feb 17

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Dec 20

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Oct 28

Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

Aug 27

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Aug 23

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Jun 19

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Dec 04

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

Aug 30

Does Ascentage Pharma Group International (HKG:6855) Have A Healthy Balance Sheet?

Oct 04

業績と収益の成長予測

SEHK:6855 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2,352	774	894	811	6
12/31/2025	497	-945	-934	-809	6
12/31/2024	988	-353	-365	-260	6
6/30/2024	903	-360	-751	-712	N/A
3/31/2024	563	-643	-767	-719	N/A
12/31/2023	222	-926	-783	-726	N/A
9/30/2023	239	-902	-798	-707	N/A
6/30/2023	257	-879	-814	-687	N/A
3/31/2023	233	-881	-852	-671	N/A
12/31/2022	210	-883	-891	-654	N/A
9/30/2022	160	-848	-922	-620	N/A
6/30/2022	111	-812	-954	-586	N/A
3/31/2022	69	-797	-997	-595	N/A
12/31/2021	28	-782	-1,041	-605	N/A
9/30/2021	25	-759	-1,021	-635	N/A
6/30/2021	23	-735	-1,000	-665	N/A
3/31/2021	18	-706	-931	-637	N/A
12/31/2020	12	-678	-861	-610	N/A
9/30/2020	14	-922	-798	-576	N/A
6/30/2020	15	-1,167	-735	-542	N/A
3/31/2020	15	-1,324	-638	-501	N/A
12/31/2019	15	-1,481	-542	-460	N/A
9/30/2019	11	-1,171	-454	-399	N/A
6/30/2019	7	-862	-366	-338	N/A
3/31/2019	7	-604	-310	-288	N/A
12/31/2018	7	-345	-253	-238	N/A
12/31/2017	6	-119	N/A	-108	N/A
12/31/2016	8	-108	N/A	-46	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 6855今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 6855今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 6855今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 6855の収益 ( 26.6% ) Hong Kong市場 ( 7.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: 6855の収益 ( 26.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 6855の自己資本利益率は、3年後には非常に高くなると予測されています ( 49.8 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/23 11:18
終値	2024/12/23 00:00
収益	2024/06/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Ascentage Pharma Group International 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。14

アナリスト	機関
Yang Huang	BofA Global Research
Jin Zhang	China International Capital Corporation Limited
Wangbin Zhou	China International Capital Corporation Limited

Ascentage Pharma Group International 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 40%

Forecast to breakeven in 2026

Consensus EPS estimates fall by 15%

Consensus revenue estimates fall by 12%

Consensus revenue estimates decrease by 22%, EPS upgraded

Recent updates

What Ascentage Pharma Group International's (HKG:6855) P/S Is Not Telling You

Ascentage Pharma Releases the Safety and Efficacy Data of the Novel Drug Candidate, Olverembatinib (HQP1351) in Combination the Company's Investigational Novel Bcl-2 Inhibitor, Lisaftoclax

Ascentage Pharma Announces New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List

Ascentage Pharma Appoints Marina S. Bozilenko and Debra Yu as Independent Non-Executive Directors

Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC

First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023)

Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up

Consensus revenue estimates increase by 40%

Forecast to breakeven in 2026

Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023)

New major risk - Revenue and earnings growth

Ascentage Pharma Clears to Initiate A Registrational Phase III Study of Lisaftoclax, by the Center for Drug Evaluation of China National Medical Products Administration

Ascentage Pharma Group International to Report First Half, 2024 Results on Aug 22, 2024

New minor risk - Shareholder dilution

Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib (HQP1351)

New minor risk - Share price stability

Ascentage Pharma Group International Announces Board and Committee Changes

Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%

Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

Consensus EPS estimates fall by 15%

Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Ascentage Pharma Group International, Annual General Meeting, May 10, 2024

Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022)

Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024

Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib (HQP1351) in Patients with Chronic-Phase Chronic Myeloid Leukemia

Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib

Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR

Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients

Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc

Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia

Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE

Consensus revenue estimates fall by 12%

Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022)

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Announces Clearance for Global Registrational Phase III Trial

Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023

Ascentage Pharma Group International Receives Clearance from the U.S. Food and Drug Administration to Initiate A Phase 3 Registrational Trial of Lisaftoclax

Ascentage Pharma Group International Announces CDE's Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ All)

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Ascentage Pharma Group International Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

Ascentage Pharma Group International Recommends Breakthrough Therapy Designation in China for the Treatment of Sdh-Deficient GIST

Ascentage Pharma Group International Presents Results from Four Studies at 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates decrease by 22%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ascentage Pharma Group International has completed a Follow-on Equity Offering in the amount of HKD 550.125 million.

Ascentage Pharma Group International's Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

Ascentage Pharma Group International Releases Preliminary Results from a Global Phase II Study of Lisaftoclax

Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Ascentage Pharma's Global Industrial Base Obtains Drug Production Enterprise License

Ascentage Pharma Group International Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies

Ascentage Pharma Group International Announces Released Results from A Phase I Study of the Investigational Inhibitor of Apoptosis Protein (Iap) Antagonist Apg-1387 in Chinese Patients with Chronic Hepatitis B

Ascentage Pharma Releases Phase I Results of Iap Antagonist Apg-1387 in an Oral Report Showing Potential for Functionally Curing Chb

Co-Founder recently bought HK$159k worth of stock

Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, At the ASH Annual Meeting

Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

Ascentage Pharma Announces Phase I/Ii Data of Olverembatinib (Hqp1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-In-Class Potential

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

First half 2022 earnings released: CN¥1.54 loss per share (vs CN¥1.53 loss in 1H 2021)